Leader of Global
HLB navigates the way to the future by developing
First-in-class drugs with continuous innovation and challenges.
About the Progress of the Global Ri...
∙ On February 26, HLB signed a binding term sheet with Adenchen Laboratories, the original developer of Rivoceranib, t...
Apealea completes Pre-NDA meeting
On April 30th, Oasmia pharmaceutical AB (Oasmia) held FDA's ovarian cancer pre-NDA meeting for Apealea, which Elevar Th...
HLB confirms Superior mPFS of Phase...
HLB announced on the 21st that the targeted anti-cancer drug Rivoceranib showed superior mPFS compared to the control...
HLB opens the result of Phase III R...
HLB announced on the 18th that the results of the Rivoceranib Thyroid Cancer Phase 3 clinical trials will be released...
Low-dose apatinib monothe...
AbstractThe therapeutic regimen for small cell lung cancer (SCLC)...
Tumor Angiogenesis and An...
AbstractAngiogenesis is the process through which novel blood ves...